Abstract
Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.
Keywords: Cancer epigenetics, DNA methyltransferase inhibitor, Epi-drugs, Epi-miRs, Histone deacetylase inhibitor.
Current Cancer Drug Targets
Title:Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Volume: 16 Issue: 9
Author(s): Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi and Hamed Mirzaei
Affiliation:
Keywords: Cancer epigenetics, DNA methyltransferase inhibitor, Epi-drugs, Epi-miRs, Histone deacetylase inhibitor.
Abstract: Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.
Export Options
About this article
Cite this article as:
Salarinia Reza, Sahebkar Amirhossein, Peyvandi Mostafa, Mirzaei Reza Hamid, Jaafari Reza Mahmoud, Riahi Matbou Maryam, Ebrahimnejad Hamed, Nahand Sadri Javid, Hadjati Jamshid, Asrami Ostadi Mobina, Fadaei Sara, Salehi Rasoul and Mirzaei Hamed, Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009616666151207110143
DOI https://dx.doi.org/10.2174/1568009616666151207110143 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine The Therapeutic Potential of Gallium-Based Complexes in Anti-Tumor Drug Design
Letters in Drug Design & Discovery Meet Our Editorial Board Member:
Recent Patents on Anti-Infective Drug Discovery Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science Efficient Growth Inhibition of Human Osteosarcoma Cells Using a Peptide Derived from the MDM-2-Binding Site of p53
Protein & Peptide Letters Hydrogen Sulphide and Pain
Inflammation & Allergy - Drug Targets (Discontinued) Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer
Current Cancer Drug Targets From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism The DNA Methylation Machinery as a Therapeutic Target
Current Drug Targets Application of Nanomaterials in Water Treatment: Arsenic and Natural Organic Matter Removal
Recent Patents on Nanotechnology Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors
Current Pharmaceutical Design microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Proteomics as a Tool in the Pharmaceutical Drug Design Process
Current Pharmaceutical Design Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Current Pharmaceutical Design Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design